Premium
Treatment patterns with topicals, traditional systemics and biologics in psoriasis – a S wedish database analysis
Author(s) -
Svedbom A.,
Dalén J.,
Mamolo C.,
Cappelleri J.C.,
Petersson I.F.,
Ståhle M.
Publication year - 2015
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.12494
Subject(s) - medicine , medical prescription , prescription drug , database , pharmacology , computer science
Background Little data exist on real‐world treatment patterns in psoriasis, especially from European settings. Objective To estimate, for topicals, systemics and biologics, the time to non‐persistency, switching, augmentation and insufficient treatment result (only for biologics), as well as to estimate the time to restart, in patients treated with each treatment class in Sweden based on registry data. Methods This database analysis utilized data from patients with psoriasis from several Swedish administrative registers. Patients were identified through combinations of diagnoses from two regional registers and filled prescriptions for relevant treatments from the Swedish Prescribed Drug Register. Kaplan–Meier time‐to‐event (‘survival’) functions were estimated with relevant treatment events as failure and the proportions of patients having experienced an event at specific time‐points were derived from the failure rates. Results For topicals, systemics and biologics the number of indexed treatment episodes were 25 396, 2963, and 628 respectively. One year after treatment initiation, the proportion of patients who were classed as non‐persistent with topicals, systemics and biologics were estimated at 88.3%, 47.9% and 43.2% respectively. Among patients who remained persistent, within 1 year of treatment start the proportions of treatment episodes in which patients were augmented were estimated at 56.0% for topicals, 45.3% for systemics and 58.9% for biologics. In addition, within 1 year of non‐persistence, 49.0% of topicals, 60.8% of systemics and 80.2% of biologics treatment episodes were re‐initiated, with 35.4–52.5% re‐initiated on the non‐persistent treatment depending on treatment class. In addition, among patients on biologics, 29.2% of treatment episodes had an insufficient treatment result within 1 year of treatment start. Conclusion Persistency to psoriasis treatments may be sub‐optimal and patients who remain persistent relatively frequently receive augmentation therapy or switch to another therapy. Therefore, current treatment options in psoriasis may be insufficient.